# LATE STAGE ADJUVANT MIMICS BASED ON TLR4 AGONISTS

> **NIH NIH N43** · PAI LIFE SCIENCES, INC. · 2022 · $597,953

## Abstract

The proprietary combination adjuvants AS01 and AS04 are used in approved vaccines (Shingrix and Cervarix, respectively). Another successful adjuvant, GLA-SE, is currently in late-stage clinical trials. To make these classes of adjuvants available to vaccine developers, the contractor is developing functional mimics for low-cost and effective vaccines against emerging diseases and to address major health gaps worldwide.

## Key facts

- **NIH application ID:** 10706777
- **Project number:** 75N93022C00004-0-9999-1
- **Recipient organization:** PAI LIFE SCIENCES, INC.
- **Principal Investigator:** DARRICK CARTER
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $597,953
- **Award type:** —
- **Project period:** 2022-01-10 → 2024-01-09

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10706777

## Citation

> US National Institutes of Health, RePORTER application 10706777, LATE STAGE ADJUVANT MIMICS BASED ON TLR4 AGONISTS (75N93022C00004-0-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10706777. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*